Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06446765 · ClinicalTrials.gov registry record · Phase 2
Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
A Phase 2 study of Borderline Personality Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06446765: Recruiting Phase 2 study of Borderline Personality Disorder, sponsored by Yale University.
NCT06446765 is a Phase 2 study of Borderline Personality Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 150 participants, above the 98-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (53% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06446765, a Phase 2 study of Borderline Personality Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the ability of mindfulness-based real time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to increase the benefits of evidence-based psychotherapy for adults with Borderline Personality Disorder (BPD).
Primary Outcome
Defined as within-DMN connectivity as the resting state seed-based connectivity between core nodes of medial prefrontal cortex (mPFC) and posterior cingulate cortex (PCC). Change = post-NF within-DMN connectivity - pre-NF within-DMN connectivity.
Conditions Studied
Interventions
- BEHAVIORAL mindfulness-based Neurofeedback
- OTHER control Neurofeedback
Study Locations (1)
Connecticut
- Connecticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2026-05-30 |
| Phase | Phase 2 |
What NCT06446765 shows while recruiting
NCT06446765 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 98-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (53% higher).
The record links to 1 condition, with Borderline Personality Disorder appearing as the primary indexed condition, and to 2 interventions - of which mindfulness-based Neurofeedback is the first listed.
NCT06446765 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06446765 about?
NCT06446765 is a clinical study titled "Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder". The purpose of this study is to test the ability of mindfulness-based real time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to increase the benefits of evidence-based psychotherapy for adults with Borderline Personality Disorder (BPD).
What is the current status of trial NCT06446765?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-03-13. Estimated completion is 2026-05-30.
What conditions does trial NCT06446765 study?
This clinical trial studies the following conditions: Borderline Personality Disorder.
What interventions are being tested in trial NCT06446765?
The interventions under investigation include: mindfulness-based Neurofeedback (BEHAVIORAL), control Neurofeedback (OTHER).
Who is sponsoring clinical trial NCT06446765?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06446765 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Personality Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06446765's enrollment target sits among peer trials
150 3rd of 16 higher than 14 of 16 other Borderline Personality Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Borderline Personality Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MDMA in Borderline Personality Disorder
RECRUITING · Phase 2
-
Treatment of Suicidal Women With Borderline Personality Disorder
COMPLETED · Phase 2
-
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
COMPLETED · Phase 2
-
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
RECRUITING · NA
-
Cognitive Reappraisal Training for Borderline Personality (BPD)
RECRUITING · NA
-
Treatment of Borderline Personality Disorder With rTMS
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI